NCT01301157

Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 294 (actual)
• Sponsor: Maruho Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the efficacy and safety of M518101 and the dose relationship among two doses of M518101 and placebo in male and female plaque psoriasis patients.

Detailed description

This study is to evaluate the efficacy and safety of M518101 and the dose response relationship among two doses of M518101 and placebo in male and female plaque psoriasis patients and to confirm the persistence of the effect of M518101.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	M518101	Proper quantity twice a day
DRUG	placebo	Proper quantity twice a day
DRUG	Dovonex	Proper quantity twice a day

Timeline

• Start date: 2011-02-01
• Primary completion: 2012-01-01
• First posted: 2011-02-23
• Last updated: 2015-11-05

Locations

32 sites across 1 country: United States